Ion Beam Applications 향후 성장

Future 기준 점검 4/6

Ion Beam Applications (는) 각각 연간 30.2% 및 5.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 36.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 24.7% 로 예상됩니다.

핵심 정보

30.2%

이익 성장률

36.75%

EPS 성장률

Medical Equipment 이익 성장	16.4%
매출 성장률	5.6%
향후 자기자본이익률	24.70%
애널리스트 커버리지	Low
마지막 업데이트	18 Jun 2025

최근 향후 성장 업데이트

Recent updates

Additional Considerations Required While Assessing Ion Beam Applications' (EBR:IBAB) Strong Earnings

May 05

Actinium-225 Production Expansion Will Capitalize On Next-Generation Cancer Treatments

Mar 23 Proton Therapy installations and clinical evidence driving competitive advantage, with expected growth in service revenues and improved market access, enhancing net and gross margins.

Ion Beam Applications SA (EBR:IBAB) Shares Fly 25% But Investors Aren't Buying For Growth

Oct 08

Is Now An Opportune Moment To Examine Ion Beam Applications SA (EBR:IBAB)?

Sep 19

It's Unlikely That The CEO Of Ion Beam Applications SA (EBR:IBAB) Will See A Huge Pay Rise This Year

Jun 06

Further Upside For Ion Beam Applications SA (EBR:IBAB) Shares Could Introduce Price Risks After 29% Bounce

Mar 25

Is Ion Beam Applications (EBR:IBAB) Using Too Much Debt?

Nov 07

Ion Beam Applications (EBR:IBAB) Has Some Way To Go To Become A Multi-Bagger

Oct 05

Ion Beam Applications (EBR:IBAB) Is Investing Its Capital With Increasing Efficiency

Jan 31

Is Ion Beam Applications (EBR:IBAB) A Risky Investment?

Sep 28

Here's Why Shareholders May Want To Be Cautious With Increasing Ion Beam Applications SA's (EBR:IBAB) CEO Pay Packet

Jun 01

Ion Beam Applications' (EBR:IBAB) Returns On Capital Are Heading Higher

May 29

Does Ion Beam Applications SA (EBR:IBAB) Have A Place In Your Dividend Stock Portfolio?

Apr 20

Is Ion Beam Applications (EBR:IBAB) A Risky Investment?

Mar 30

Should You Use Ion Beam Applications' (EBR:IBAB) Statutory Earnings To Analyse It?

Feb 10

What Type Of Shareholders Make Up Ion Beam Applications SA's (EBR:IBAB) Share Registry?

Jan 06

Does This Valuation Of Ion Beam Applications SA (EBR:IBAB) Imply Investors Are Overpaying?

Dec 10

Ion Beam Applications' (EBR:IBAB) Shareholders Are Down 64% On Their Shares

Nov 17

Ion Beam Applications SA (EBR:IBAB) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Aug 20

Estimating The Intrinsic Value Of Ion Beam Applications SA (EBR:IBAB)

Jul 21

Our Take On Ion Beam Applications SA's (EBR:IBAB) CEO Salary

Jun 16

이익 및 매출 성장 예측

ENXTBR:IBAB - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	620	36	39	49	2
12/31/2026	600	35	46	58	3
12/31/2025	566	23	9	18	3
12/31/2024	498	9	-18	-11	N/A
9/30/2024	501	9	-27	-19	N/A
6/30/2024	466	8	-37	-27	N/A
3/31/2024	447	-1	-34	-23	N/A
12/31/2023	467	-9	-32	-20	N/A
9/30/2023	419	-14	-45	-33	N/A
6/30/2023	371	-19	-59	-47	N/A
3/31/2023	366	-7	-22	-13	N/A
12/31/2022	361	6	14	22	N/A
9/30/2022	349	5	54	60	N/A
6/30/2022	336	4	93	98	N/A
3/31/2022	324	4	87	93	N/A
12/31/2021	313	4	82	87	N/A
9/30/2021	326	23	83	87	N/A
6/30/2021	339	42	83	87	N/A
3/31/2021	326	37	90	94	N/A
12/31/2020	312	32	96	100	N/A
9/30/2020	288	16	N/A	N/A	N/A
6/30/2020	264	1	69	73	N/A
3/31/2020	273	4	56	61	N/A
12/31/2019	283	8	44	49	N/A
9/30/2019	325	5	N/A	N/A	N/A
6/30/2019	295	-2	-9	11	N/A
3/31/2019	276	-3	-23	-4	N/A
1/1/2019	257	-4	-37	-19	N/A
9/30/2018	229	-25	N/A	-40	N/A
6/30/2018	175	-45	N/A	-61	N/A
3/31/2018	206	-43	N/A	-53	N/A
12/31/2017	236	-42	N/A	-45	N/A
9/30/2017	311	-14	N/A	-30	N/A
6/30/2017	335	12	N/A	-15	N/A
3/31/2017	332	18	N/A	-16	N/A
12/31/2016	329	25	N/A	-17	N/A
9/30/2016	312	40	N/A	-1	N/A
6/30/2016	294	55	N/A	15	N/A
3/31/2016	282	58	N/A	30	N/A
1/1/2016	270	61	N/A	45	N/A
10/1/2015	257	46	N/A	31	N/A
6/30/2015	243	31	N/A	17	N/A
3/31/2015	232	26	N/A	16	N/A
12/31/2014	221	21	N/A	15	N/A
9/30/2014	217	9	N/A	31	N/A

애널리스트 향후 성장 전망

수입 대 저축률: IBAB 의 연간 예상 수익 증가율(30.2%)이 saving rate(1.9%)보다 높습니다.

수익 vs 시장: IBAB 의 연간 수익(30.2%)이 Belgian 시장(14.3%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: IBAB 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: IBAB 의 수익(연간 5.6%)이 Belgian 시장(연간 7.5%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: IBAB 의 수익(연간 5.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: IBAB의 자본 수익률은 3년 후 24.7%로 높을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/08/07 01:26
종가	2025/08/07 00:00
수익	2024/12/31
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Ion Beam Applications SA는 8명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Tim Heirwegh	BNP Paribas Exane
Laura Roba	Degroof Petercam
Mathew Fernley	Haitong Bank S.A.

Ion Beam Applications 향후 성장

Future 기준 점검 4/6

핵심 정보

최근 향후 성장 업데이트

Consensus EPS estimates fall by 12%

Price target decreased by 7.9% to €16.67

Ion Beam Applications SA Provides Earnings Guidance for the Year 2025

Price target increased by 7.5% to €18.10

Consensus EPS estimates fall from profit to €0.16 loss

Price target increased by 12% to €17.50

Recent updates

New minor risk - Share price stability

Consensus EPS estimates fall by 12%

Price target decreased by 7.9% to €16.67

Additional Considerations Required While Assessing Ion Beam Applications' (EBR:IBAB) Strong Earnings

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Ion Beam Applications SA Provides Earnings Guidance for the Year 2025

Actinium-225 Production Expansion Will Capitalize On Next-Generation Cancer Treatments

Ion Beam Applications SA, Annual General Meeting, Jun 11, 2025

Ion Beam Applications SA to Report Q3, 2025 Results on Nov 20, 2025

Price target increased by 7.5% to €18.10

Iba Announces Stepping Down of Soumya Chandramouli as Chief Financial Officer, Effective 31 January 2025

Ion Beam Applications SA (EBR:IBAB) Shares Fly 25% But Investors Aren't Buying For Growth

Is Now An Opportune Moment To Examine Ion Beam Applications SA (EBR:IBAB)?

Investor sentiment improves as stock rises 24%

Consensus EPS estimates fall from profit to €0.16 loss

First half 2024 earnings released

Ion Beam Applications SA to Report Q1, 2025 Results on May 22, 2025

Dividend of €0.12 announced

It's Unlikely That The CEO Of Ion Beam Applications SA (EBR:IBAB) Will See A Huge Pay Rise This Year

Price target increased by 12% to €17.50

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Further Upside For Ion Beam Applications SA (EBR:IBAB) Shares Could Introduce Price Risks After 29% Bounce

Full year 2023 earnings released

Ion Beam Applications SA to Report First Half, 2024 Results on Aug 29, 2024

Ion Beam Applications S.A., CMI Inc. and Life Molecular Imaging Announce Japanese Approval for the Reimbursement of Amyloid-Pet Diagnostic Neuraceq in Alzheimer's Disease

Consensus EPS estimates fall by 20%

Ion Beam Applications SA, Annual General Meeting, Jun 12, 2024

Is Ion Beam Applications (EBR:IBAB) Using Too Much Debt?

New minor risk - Share price stability

Ion Beam Applications S.A Plans Total System Restoration on its First-Ever Proton Therapy Installation

Price target decreased by 18% to €18.00

Insufficient new directors

Price target increased by 26% to €22.30

Full year 2022 earnings released

Ion Beam Applications SA to Report Q1, 2023 Results on May 18, 2023

Price target increased to €19.25

Ion Beam Applications (EBR:IBAB) Has Some Way To Go To Become A Multi-Bagger

First half 2022 earnings released: €0.059 loss per share (vs €0.066 loss in 1H 2021)

Ion Beam Applications SA Continues to Shape the Future of Proton Therapy At Estro 2022 Annual Congress

Ion Beam Applications SA (ENXTBR:IBAB) acquired Modus Medical Devices Inc.

Full year 2021 earnings: EPS exceeds analyst expectations

Price target increased to €17.75

Investor sentiment improved over the past week

Ion Beam Applications (EBR:IBAB) Is Investing Its Capital With Increasing Efficiency

IBA Launches Compact Low-Energy Cyclotron, Cyclone® KEY

First half 2021 earnings released: €0.066 loss per share (vs €0.41 loss in 1H 2020)

First half 2021 earnings released: €0.066 loss per share (vs €0.41 loss in 1H 2020)

First half 2021 earnings released: €0.066 loss per share (vs €0.41 loss in 1H 2020)

Is Ion Beam Applications (EBR:IBAB) A Risky Investment?

First half 2021 earnings released

Ion Beam Applications S.A. Announces Launch of a Large-Scale, Multi-Institutional, Randomized Controlled Clinical Trial

Price target increased to €15.00

Here's Why Shareholders May Want To Be Cautious With Increasing Ion Beam Applications SA's (EBR:IBAB) CEO Pay Packet

Ion Beam Applications' (EBR:IBAB) Returns On Capital Are Heading Higher

Does Ion Beam Applications SA (EBR:IBAB) Have A Place In Your Dividend Stock Portfolio?

Is Ion Beam Applications (EBR:IBAB) A Risky Investment?

Full year 2020 earnings released

IBA (Ion Beam Applications S.A. and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Diagnostic Radioisotope Technetium-99m (Tc-99m)

Ion Beam Applications SA Receives Down Payment from National Cancer Center Korea for A Second Proteus® System

Should You Use Ion Beam Applications' (EBR:IBAB) Statutory Earnings To Analyse It?

Price target raised to €12.60

Ion Beam Applications SA to Report Q3, 2021 Results on Nov 18, 2021

New 90-day high: €13.46

What Type Of Shareholders Make Up Ion Beam Applications SA's (EBR:IBAB) Share Registry?

Does This Valuation Of Ion Beam Applications SA (EBR:IBAB) Imply Investors Are Overpaying?

Ion Beam Applications' (EBR:IBAB) Shareholders Are Down 64% On Their Shares

New 90-day high: €11.96

New 90-day high: €11.68

Ion Beam Applications SA Signs Contract for the First End-To-End Rhodotron® Duo Solution for Multi-Purpose Irradiation in Taiwan